Incyte Announces FDA Approval of Opzelura Cream for Vitiligo
Incyte (INCY) announced today, July 19, 2022, that the United States Food and Drug Administration (FDA) has approved Opzelura™ (ruxolitinib) cream 1.5% for the topical treatment of nonsegmental vitiligo in 12 years old patients and older.
Opzelura is the first and only FDA-approved treatment for . . .
This content is for paid subscribers.
Impacting News July 20, 2022